• Portrait of Paul Fernyhough
  • Professor

    Max Rady College of Medicine
    Pharmacology and Therapeutics
    St. Boniface Hospital Albrechtsen Research Centre
    R4046 – 351 Tache Avenue
    University of Manitoba
    Winnipeg, Manitoba R2H 2A6

    Phone: 204-235-3692
    pfernyhough@sbrc.ca

Research summary

Dr. Paul Fernyhough is leading groundbreaking research on the underlying mechanisms of nerve damage in patients with diabetes and the link between Alzheimer's disease and Type 2 diabetes. Through his studies, Dr. Fernyhough is identifying key signaling pathways that are impaired in animal models of neuropathy and Alzheimer's disease, with the goal of developing new treatments for these debilitating conditions. As the World Health Organization predicts that by 2025 there will be 300 million sufferers from diabetes worldwide, the impact of Dr. Fernyhough's research has the potential to be truly significant. He is  affiliated with several research groups, including Diabetes Action Canada, WinSanTor Inc. and Manitoba Neuroscience Network, where his research is making a real impact in the field of diabetic complications and peripheral neuropathy. He is also known for his research on cholinergic signaling, GPCR signaling, bioenergetics and drug design, which is helping to further our understanding of these complex conditions.

 

  • Research affiliations

    Director, division of neurodegenerative disorders, St. Boniface Hospital Albrechtsen Research Centre

    Research groups

    Diabetes Action Canada – SPOR in chronic disease in area of diabetic complications

    WinSanTor Inc. – Co-founder of this small start-up biotech company that is supporting clinical trials in the area of peripheral neuropathy.

    Manitoba Neuroscience Network

  • Research interests

    Mechanisms of nerve damage

    Cholinergic signaling

    GPCR signaling

    Bioenergetics

    Drug design

    Muscarinic receptors

  • Keywords

    • Alzheimer's disease
    • Antimuscarinic drugs
    • Axonal degeneration
    • Bioenergetics
    • Cholinergic signaling
    • Diabetes
    • Drug design
    • GPCR signaling
    • Mitochondria
    • Neuropathy

Biography

Dr. Paul Fernyhough is a renowned researcher in the field of neurodegeneration and neuronal regeneration. Born and educated in East London, UK, he received his Bachelor of Science degree in biological sciences at the University of Essex and went on to perform his PhD in biochemistry at the University of Sheffield.

After completing his PhD, Dr. Fernyhough embarked on a journey of postdoctoral research, honing his skills and expanding his knowledge at esteemed institutions such as Colorado State University, Kings College London, and as a Wellcome Trust Postdoctoral Fellow at St. Bartholomew’s Medical College.

In 1998, Dr. Fernyhough joined the School of Biological Sciences (now the Faculty of Life Sciences) at the University of Manchester as a fully tenured lecturer. He spent over five years at the University of Manchester before moving to Canada to join the Max Rady College of Medicine as a professor of pharmacology and therapeutics.

Throughout his career, Dr. Fernyhough has been dedicated to understanding the mechanisms of nerve damage and identifying key signaling pathways that are impaired in animal models of neuropathy and Alzheimer’s disease. His research interests include cholinergic signaling, GPCR signaling, bioenergetics, drug design, and muscarinic receptors.

In addition to his academic pursuits, Dr. Fernyhough is also the director of the division of neurodegenerative disorders at the St. Boniface Hospital Albrechtsen Research Centre, and is a co-founder of WinSanTor Inc., a small start-up biotech company that supports clinical trials in the area of peripheral neuropathy. He is also affiliated with the Manitoba Neuroscience Network.

Dr. Fernyhough's research is making significant contributions towards improving the lives of millions of people suffering from diabetes and other neurodegenerative disorders.

Education

Doctor of Philosophy in Biochemistry, University of Sheffield (1984)

Bachelor of Science in Biology, University of Essex (1981) with 2.1 Honours

Contact us

Pharmacology and Therapeutics
Max Rady College of Medicine
A205 Chown Bldg., 753 McDermot Avenue
University of Manitoba (Bannatyne campus)
Winnipeg, MB R3E 0T6 Canada

204-789-3553